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Abstract
Breast and ovarian cancers now account for one in three cancers in Indian women and their incidence is ris-
ing. Major differences in the clinical presentation of breast and ovarian cancers exist between India and the
United Kingdom. For example, Indian patients with breast cancer typically present a decade earlier than in
the UK. Reasons for this could be multifactorial, including differences in underlying biology, environmental
risks, and other systematic factors including access to screening. One possible explanation lies in variable inci-
dence or penetrance of germline mutations in genes such as BRCA1 and BRCA2. We performed a methodical
database and literature review to investigate the prevalence and spectrum of high-risk cancer susceptibility
genes in Indian patients with breast and ovarian cancers. We identiﬁed 148 articles, but most studies were
small, with inconsistent inclusion criteria and based on heterogeneous technologies, so that mutation fre-
quency could not be reliably ascertained. Data were also often lacking on penetrance, histopathology, and sur-
vival outcomes. After ﬁltering out unsuitable studies, only 13 remained, comprising 1028 patients. Large-scale
research studies are urgently needed to determine mutation prevalence, spectra, and clinico-pathological fea-
tures, and hence derive guidelines for screening, treatment, and prevention speciﬁc to the Indian population.
Key words: BRCA1; BRCA2; hereditary cancer; sporadic cancer; India; breast cancer; ovarian cancer
Introduction
The global cancer burden is expected to increase from
14.1 million new cases and 8.2 million deaths in 2012, to
21.7 million cases and 13 million deaths by 2030.
However, these large numbers are contrasted by the
very diverse nature of cancer that makes every patient
unique. Precision medicine has enormous potential to
transform cancer care by identifying genomic and
epigenetic markers for screening, treatment, and prog-
nosis. These gains are particularly relevant for countries
such as India, grappling with both a rising cancer bur-
den and competing demands for essential health care.
India’s cancer burden, currently estimated at over 1.5
million new cases is predicted to nearly double in the
next 20 years, with age-adjusted mortality rates of 64.5
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per 100 000 (GLOBOCAN 2012).1 Cumulatively, breast,
cervical, ovarian, and uterine cancers account for more
than 70% of cancers in women in India, thus establish-
ing tackling women’s cancers as high priority for
healthcare providers and research.2
Signiﬁcant phenotypic differences exist in breast
and ovarian cancers between patients in India and in
the UK. The incidence of breast and ovarian cancer is
relatively low in India in comparison with the UK:
breast cancer 23.8 versus 92.9 cases per 100 000 women
in the UK, ovarian cancer 4.9 versus 11.7/100 000
women in the UK (GLOBOCAN 2012).1 However, a high
proportion (~11-26%) of Indian patients with breast
cancer present at ages younger than 35 years.3
Conversely, approximately half of newly diagnosed
breast and ovarian cancer cases occur in women aged
65 years and older in the UK, compared with only 15%
in India (Fig. 1). The incidence of the more aggressive
histological type of breast cancer, triple-negative dis-
ease, is also estimated to be higher at 31% in India,
nearly double that of the UK.5 Breast cancer incidence
also ﬂuctuates substantially across India, with age-
standardised incidence rates varying between 41/100 000
rate in urban centres such as New Delhi and 12.4/100 000
in rural cancer registries, thus adding a further layer of
complexity.6
These phenotypic differences could be a result of dif-
ferences in tumour biology such as differences in the
incidence of high-risk germline susceptibility genes,
environmental modiﬁers,7,8 or systematic factors such
as access to screening and treatment. Germline muta-
tions in high-risk susceptibility genes (e.g. BRCA1,
BRCA2) account for 5-10% of breast cancers and up to
20% of ovarian cancers in white Europeans.9–12 Women
with a germline BRCA1 mutation have a lifetime risk of
ovarian cancer by age 70 years of up to 63% and of
breast cancer by age 70 years of up to 85%.13 Risks of
ovarian and breast cancers in women by age 70 years
among BRCA2 carriers are reported to be up to 27% and
84%, respectively. Other genes in which germline muta-
tions confer susceptibility to breast and/or ovarian can-
cer, albeit with lower frequency and penetrance include
PALB2, TP53, PTEN, CDH1, STK11, CHEK2, RAD51, and
ATM.14
We systematically reviewed the literature and rele-
vant data repositories to characterise the prevalence
and spectrum of germline variants in breast and ovar-
ian cancer susceptibility genes in the Indian population,
including putative BRCA1 and BRCA2 founder muta-
tions. We excluded SNPs with high frequency in the
population. We investigated the literature for details of
clinical, family history, pathology, and survival data in
these patients.
Methods
Search strategy, inclusion and exclusion criteria
A comprehensive literature search was performed to
include articles published between 1 January 1990 and 1
December 2016 using the following search terms on eth-
nicity, condition, and high penetrance genes (Table 1):
‘India and (breast cancer or ovarian cancer) and (BRCA1
or BRCA2 or PALB2 or TP53 or PTEN or CDH1 or STK11 or
CHEK2 or RAD51C or RAD51D or ATM or BARD1 or NBN
or MLH1 or MSH2 or MSH6 or PMS2 or EPCAM)’ in
EMBASE and PubMed/Medline to identify relevant pub-
lished and unpublished studies as well as studies in
progress. Further searches were carried out in the BIC15
database using the keyword ‘Indian’ in the ethnicity
ﬁelds and also in the ClinVar database.16 Additional
database searches included the 1000genomes16, TCGA,13
COSMIC18, dbSNP19, ICGC20, HGMD21, ExAC22, and the
GWAS catalog23.
This initial search was supplemented by checking
reference lists, and contact with authors of included
studies for information on any relevant published or
unpublished studies. No language restrictions were
applied. Two reviewers assessed titles, abstracts, and
keywords to select potentially relevant studies from the
retrieved list of articles.
Figure 1. Comparisons between UK and India by age of newly diag-
nosed BOC incidence in women.3
Table 1. List of genes, with high and moderate penetrance,
used in the search terms in association with breast and
ovarian cancer as well as Lynch syndrome.
High-penetrance
genes
Moderate-
penetrance genes
Lynch syndrome
genes
BRCA1 CHEK2 MLH1
BRCA2 RAD51C MSH2
PALB2 RAD51D MSH6
TP53 ATM PMS2
PTEN BARD1 EPCAM
CDH1 NBN
STK11
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Study selection criteria for literature search
All studies included in the analysis met the following
inclusion criteria: (i) data reported on any genes
included in Table 1; (ii) at least 10 patients of Indian ori-
gin; and (iii) contained DNA sequence variation data.
The susceptibility genes selected are those commonly
tested in clinical practice. Lynch syndrome genes were
included as they confer susceptibility to ovarian cancer
in addition to colon and uterine cancers (Table 1).
Importantly, inclusion was not restricted by NCCN or
Manchester deﬁnitions of familial risk to ensure broad
inclusion of studies with available data.
The exclusion criteria were: (i) articles containing
data limited to loss of heterozygosity and/or methylation
studies; (ii) duplicate publications; (iii) studies that did
not perform direct DNA sequencing to validate variants
detected by PCR-based techniques using re-ampliﬁed
genomic DNA; and (iv) studies that did not screen the
entire susceptibility gene. If studies had overlapping
data, only the latest or largest study was included
(Fig. 2).
The ﬁrst step of a two-stage selection process
involved screening titles and abstracts. Subsequently,
for all references categorised as ‘include’ or ‘uncertain’
by both reviewers, full text was retrieved wherever pos-
sible and ﬁnal inclusion decisions were made on the
full paper. Data extraction was carried out using pre-
designed and piloted data extraction forms with
differences resolved by consensus and/or arbitration
involving a third reviewer.
Data extraction from literature search
Three reviewers extracted detailed information relating
to variants; clinical evidence, including family history
when available; clinical diagnosis; and histopathology.
The information collected included the following: year
of publication; authors’ names; journal; geographic loca-
tion of study; cancer type; genotyping methods; details
of germline variant, total numbers of cases and con-
trols; frequencies of variant carriers in cases and con-
trols; histopathology; overall and progression-free
survival where available; and age of presentation.
All variants extracted from the publications were
queried against the BIC database for BRCA1 and BRCA2
genes and ClinVar16 to conﬁrm whether they had been
reported previously by other studies and to obtain their
pathogenic classiﬁcation. The SNP identiﬁer for each of
the variants, where available, was obtained from the
dbSNP database.24
Results of literature search
Characteristics of included studies
The combined search for key terms led to the selection
of 148 articles. After screening titles, abstract, and key-
words, we extracted 120 full texts of articles considered
eligible for inclusion. After reviewing the full texts and
citations, we identiﬁed 67 studies meeting the inclu-
sion criteria of which 31 contained data suitable for
extraction. Of the 31 articles, only 13 articles contained
usable data that satisﬁed both the inclusion and exclu-
sion criteria (Fig. 2, Table 2). These publications
included familial breast and/or ovarian cancer as well
as sporadic cases. For the purposes of this review, we
used a broad deﬁnition of FEOTN (familial/early-onset/
triple-negative) based on the studies included in the
review, speciﬁcally one or more of the following: at
least one ﬁrst-degree relative with breast and/or ovar-
ian cancer irrespective of age; early onset breast and/or
ovarian cancer diagnosed with a family history; rela-
tives affected ﬁrst or second degree; triple-negative
breast cancer in an early onset case; or bilateral breast
cancer diagnosed < 50 years. Data were included from
probands and from family members who were carriers,
where given. We also included data from sporadic can-
cer patients where the paper contained this informa-
tion. However, none of the publications on sporadic
cases reviewed reported any pathogenic germline var-
iants and therefore we focused our analysis on FEOTN
cases (Fig. 2).
We identiﬁed a total of 1028 breast and/or ovarian
cancer cases from the 13 studies. A breakdown of the
number of studies from different categories of breast
and/or ovarian cancer is presented in Table 3. The
majority of the studies were conducted in or near the
Search results from combined
databases
(n = 148)
Full text retrieval (n = 120)
Publications meeting inclusion
criteria
(n = 67)
Publications included
(n = 31 of which n = 3 colorectal and
n = 1 Lynch Syndrome)
Articles excluded (n = 53)
Data not reported on the list of
susceptibility genes in
Breast/Ovarian or uterine cancer
AND at least 10 patients of Indian
ethnicity
Excluded articles (n = 36)
DNA sequence variation data not
reported
Excluded studies-LOH  AND/OR
Methylation studies
Search term: Indian/Punjab +
BOC + list of high penetrance
genes
Articles excluded (n = 18)
The PCR assay not verified by
direct sequencing and or
Non -pathogenic variants reported
Publications included
(n = 13)
Figure 2. Flow diagram illustrating the criteria for selection of publi-
cations and corresponding number of articles.
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largest cities of India with the exception of two that
were carried out within the Indian populations of
Malaysia and Singapore. The patients recruited in any
study usually resided in or near the big cities, which are
densely populated and are more afﬂuent than the rural
populations of India (Fig. 3).
Table 2. Publications reporting variations in high-penetrance breast and ovarian cancer genes.
Year Geographic
location
Number
cases
Number
of
controls
Cancer
subtype
Gene names Method Title Journal
2009 South India 61 100 Breast
cancer
BRCA1 and BRCA2 Heteroduplex analysis
using CSGE and
direct sequencing
BRCA1 and BRCA2 germline
mutation analysis among Indian
women from south India:
Identiﬁcation of four novel
mutations and high-frequency
occurrence of 185delAG mutation
J Biosci;34:415
2002 North India 20 50 Breast
cancer
BRCA1 and BRCA2 Heteroduplex analysis/
USB PCR- products
sequencing kit
BRCA1 and BRCA2 in Indian patients
with breast cancer
Hum
Mutat;20:473–74
2006 Srinagar,
Jammu,
and
Kasmir,
India
63 63 Breast
cancer
BRCA1 and TP53 PCR-SSCP (single
stranded
conformational
polymorphism)
followed by direct
sequencing
BRCA1 and TP53 mutation spectrum
of breast carcinoma in an ethnic
population of Kashmir, an
emerging high-risk area
Cancer
Letters;248:308–20
2003 North India,
New Delhi
40 50 Breast
cancer
BRCA1 SSCP and direct
sequencing
BRCA1 germline mutations in Indian
familial breast cancer
Hum Mutat;21:98–9
2012 Mumbai 151 50 Breast
cancer
BRCA1 and BRCA2 PCR+direct sequencing BRCA1/BRCA2 gene mutations/SNPs
and BRCA1 haplotypes in early-
onset breast cancer patients of
Indian ethnicity
Med Oncol;29:3272-
81. doi: 10.1007/
s12032-012-0294-
9. Epub 2012 Jul 3
2006 New Delhi,
Northern
India
204 140 Breast
cancer
BRCA1 and BRCA2 Heteroduplex analysis
of PCR amplicons
using exon speciﬁc
primers
Contribution of germline BRCA1 and
BRCA2 sequence alterations to
breast cancer in Northern India
BMC Med Genet;7:75
2016 56/141 from
North
India, 63
from
South
India
141 250 Breast and
ovarian
cancer
BRCA1, BRCA2, ATM,
BRIP1, CDH1,
CHEK2, NBN,
PALB2, PTEN,
RAD51C, RAD51D,
STK11, and TP53
Illumina MiSeq and
sanger sequencing
and MLPA
(multiplex ligation-
dependant probe
ampliﬁcation)
Detection of high frequency of
mutations in a breast and/or
ovarian cancer cohort:
implications of embracing a
multi-gene panel in molecular
diagnosis in India
J Hum
Genet;61:515–22.
doi: 10.1038/
jhg.2016.4. Epub
2016 Feb 25
2008 Indian
ethnicity,
Malaysia
22 ? Breast
cancer
BRCA1 and BRCA2 DHPLC and DNA
sequencing
Evaluation of BRCA1 and BRCA2
mutations and risk-prediction
models in a typical Asian country
(Malaysia) with a relatively low
incidence of breast cancer
Breast Cancer Res;10:
R59. doi: 10.1186/
bcr2118. Epub
2008 Jul 16
2002 Trivandrum,
South
India
14 ? Breast and
ovarian
cancer
BRCA1 Conformation
sensitive gel
electrophoresis and
direct sequencing of
PCR products
Germline BRCA1 mutation analysis
in Indian breast/ovarian cancer
families
Cancer Biol
Ther;1:18–21
2007 Kerala,
South
India
102 ? Breast and
ovarian
cancer
BRCA2 Direct sequencing Novel germline mutations in BRCA2
gene among 96 hereditary breast
and breast–ovarian cancer
families from Kerala, South India
J Cancer Res Clin
Oncol;133:867–74
2004 New Delhi 65 69 Breast and
ovarian
cancer
BRCA1 and BRCA2 Direct sequencing Novel germline mutations in the
BRCA1 and BRCA2 genes in Indian
breast and breast–ovarian cancer
families
Hum Mutat;23:205
2014 Indian
ethnicity,
Malaysia
54 ? Breast
cancer
BRCA1 and BRCA2 PCR and sanger
sequencing
Recurrent mutation testing of
BRCA1 and BRCA2 in Asian breast
cancer patients identify carriers
in those with presumed low risk
by family history
Breast Cancer Res
Treat;144:635–42.
doi: 10.1007/
s10549-014-2894-x.
Epub 2014 Mar 1
2015 Chennai,
South
India
91 2 Breast and
ovarian
cancer
BRCA1, BRCA2, TP53,
RAD50, RAD52,
ATM, and TP53BP1
Illumina HiScanSQ
system and sanger
sequencing and
PCR-dHPLC
Targeted resequencing of 30 genes
improves the detection of
deleterious mutations in South
Indian women with breast and/or
ovarian cancers
Asian Pac J Cancer
Prev;16:5211–7
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Platforms used for genetic testing
Many different platforms were used for genetic testing
in the 13 studies, with the majority using PCR-based
approaches including hetero-duplex formation, single-
strand conformation polymorphism (SSCP) analysis,
denaturing high-performance liquid chromatography
(dHPLC), and Sanger sequencing.
Only two studies with a cohort size of 141 and 91
used next generation sequencing (NGS) with Illumina
HiScanSQ system, and these also reported the highest
proportions of variants in the cohort.
Study ﬁndings on prevalence of cancer
susceptibility genes
All 13 FEOTN publications reported data on BRCA1 and/
or BRCA2 and only three studies tested for other suscep-
tibility genes such as TP53, RAD50, RAD52, ATM, and
CHEK2, with mutations in these found very rarely if at
all. We therefore limited our analysis to BRCA1 and
BRCA2 genes. Twelve studies reported previously
Table 3. Breakdown of cancer subtypes from data extracted.
Type of cancer Category Total number
of cases
Number of
studies
Breast cancer Familial 529 12
Early onset 218 6
Sporadic 128 5
Uncategorised 105 2
Ovarian cancer 14 2
Breast and
ovarian
cancer
29 3
Figure 3. Geographical distribution of the cohorts from the selected studies. The size of the stars are proportional to the size of the study
cohort.
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Table 4. Previously reported pathogenic BRCA1 variants identiﬁed from the literature search that are also present in BIC and ClinVar.
HGVS annotation BIC Clinical signiﬁcance BIC
entries
BRCA1 EXON/
Intron
cDNA Protein Variant
type
Designation Class ClinVar classiﬁcation dbSNP id Number of studies
reporting variant
Total cases (does not
include controls)
Carrier Number
of cases
2 c.66_67delAG p.Leu22_Glu23LeuValfs F *185delAG 5 Pathogenic rs80357713 10 927 39 2038
20 c.5260G>T p.Glu1754Ter N E1754X 5 Pathogenic rs80357432 1 40 1 20
11 c.2864C>A p.Ser955Ter N S955X 5 Pathogenic rs80357295 1 61 1 4
11 4213delT Leu.1365->Stop N - - Pathogenic rs398122681 1 61 1 -
18 5267T->G p.Tyr1716Ter N - - Pathogenic rs397509230 1 61 1 -
11 3450delCAAG/
c.3331_3334delCAAG
p.Gln1111_Glu1112?fs F 3450del4 5 Pathogenic rs80357903 1 61 1 43
5 c.212+1G>T - SS IVS5+1G>T - Pathogenic rs80358042 1 20 1 6
20 c.5241delA p.Gln1747 = fs F 5360delA 5 Pathogenic rs80357791 1 40 1 1
13 c.4327C>T p.Arg1443ter N R1443X 5 Pathogenic rs41293455 1 22 1 131
12 c.4183C>T p.Gln1395Ter N Q1395X 5 Pathogenic rs80357260 1 124 1 28
11 c.671-1G>T - IVS IVS10-1G>T Pending Pathogenic rs80358020 1 91 1 1
11 c.5074+1G>A - SS IVS17
+1G>A
Pending Pathogenic rs80358053 1 91 1 3
11 c.3553G>T p.Glu1185Stop F - - Pathogenic rs397509081 1 43 1 -
11D c.4065_4068delTCAA p.Asn1355_Gln1356?fs F 4184del4 5 Pathogenic rs80357508 1 204 1 144
11D 3596del4/c.3477_3480delAAAG p.Ile1159Metfs F 3596del4 5 Pathogenic rs80357781 1 204 1 3
15/14 c.4485-1G>A - IVS IVS14-1G>A Pending Pathogenic rs80358189 1 151 3 2
11 c.2275C>T p.Gln759ter N Q759X 5 Pathogenic rs80356999 1 151 2 1
11 c.2338C>T p.Gln780ter N Q780X 5 Pathogenic rs80356945 1 151 2 36
11 c.3607C>T Arg1203ter N R1203X 5 Pathogenic rs62625308 1 151 1 36
3 235G>A/c.116G>A Cys39Tyr M C39Y Pending Conﬂicting interpretations of
pathogenicity, not provided.
Pathogenic (4);Uncertain
signiﬁcance (1)
rs80357498 1 151 1 5
5 c.182G>A Cys61Tyr M C61Y Pending Conﬂicting interpretations of
pathogenicity, Pathogenic
(3);Uncertain signiﬁcance (1)
rs80357093 1 151 1 6
10 c.3352C>T p.Gln1118Ter NS - Pathogenic rs397507215 1 141 2 -
15 c.4837_4838delAGinsGCC p.Ser1613Alafs Indel - Pathogenic rs730880287 1 141 2 -
16 c.5035delC p.Leu1679Terfs Indel - Pathogenic rs80357896 1 141 1 -
20 c.5251C>T p.Arg1751Ter N - Pathogenic rs80357123 1 22 1 -
11 1173G>T p.Glu352Ter N E352X Pathogenic rs80357472 1 22 1 -
2 180delA Stop22 F 180delA Pathogenic rs273902778 1 22 1 3
N = Nonsense, F = frameshift, SS = splice site, IVS = Intervening sequence ie. the intron, Indel = insertion and deletion. Recurrent variant detected in multiple studies: Vaidyanathan et al. (61 cases, 10 carriers of 185delAG), Saxena et al. (204 cases, 1 carrier of 185delAG),
Mannan et al. (141 cases, 6 carriers of 185delAG), Kumar et al. (14 cases, 1 carrier of 185delAG), Hedau et al. (124 cases, 2 carriers of 185delAG), Kang et al. (54 cases, 4 carriers of 185delAG), Rajkumar et al. (91 cases, 10 carriers of 185delAG), Juwle et al. (151 cases, 2 carriers of
185delAG), Thirthagiri et al. (65 cases, 2 carriers of 185delAG), Valarmathi et al. (65 cases, 2 carriers of 185delAG). Total: 927 cases, 39 carriers of 185delAG.
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identiﬁed pathogenic BRCA1 variants and 10 reported
novel variants they considered likely to be pathogenic.
The novel variants were not present in any of the online
databases listed in the Methods section. Initially, we
considered variants causing protein truncation only to
be likely pathogenic. We then predicted the functional
effects of non synonymous missense variants using SIFT,
PolyPhen and CADD and identiﬁed 2 additional variants,
5360A>C and 5377G>A, considered deleterious/probably
damaging by all three algorithms (Supplementary Table
1). In total, we identiﬁed 26 previously reported patho-
genic variants and 18 novel likely pathogenic variants for
BRCA1 from a total cohort of 926 (Tables 4 and 5). In
combination, the previously reported and the novel var-
iants were detected in 71/926 cases, 39 of whom carried
the ‘Ashkenazi’ 185delAG mutation.
For BRCA1, there were seven additional recurrent
mutations, ﬁve in BIC and/or ClinVar and two that were
novel (Tables 4 and 5). Of the ﬁve previously reported
variants, c.2275C>T, c.2338C>T, c.3352C>T, and
4838delAGinsGCC each occurred in two cases and the
other, c.4485-1G>A, occurred in three cases. The two
novel variants were c.1052delT and c.632insT, the for-
mer detected in four cases and the latter in two cases,
all from single studies (Table 5).
For BRCA2, there were four variants previously
reported as pathogenic in ClinVar detected in the FEOTN
cases; these were detected in 6/974 cases. The only recur-
rent variant, 6079del4, was detected in 3/974 cases from
two different studies (Table 6). The number of variants
reported to be novel and likely pathogenic was 16, and
each of these variants was detected in single cases in
single studies (Table 7). Furthermore, there were 9 non
synonymous missense variants of which only one,
c.3578T>C, was considered deleterious/probably damaging
by SIFT, POlyphen and CADD (Supplementary Table 2).
Prevalence of founder mutations in BRCA1 and
BRCA2
Ten of the 13 studies reported data on the putative foun-
der mutation BRCA1 185delAG (Fig. S1, see online sup-
plementary material). The mutation was detected in 39/
927 (4.2%) cases with breast or ovarian cancer, the
majority being from South India or Malaysians of Indian
descent. The frequency of 185delAG varied, for example
one study from New Delhi found only one carrier in 204
cases, but a high prevalence was reported in Bangalore
(10/61 cases, 0/100 controls, Fisher exact test P = 3.7×10-5)
and Chennai (10/91 cases, 0/2 controls)25,26 (Table 2).
The reported BRCA2 founder mutation 6174delT was
not detected in any of the studies included in our ana-
lysis.2 Frequencies of BRCA mutations identiﬁed in the
included studies in the Indian population are contrasted
with those of white European populations (Tables 4 and 6).
BIC and ClinVar search and additional database
search for variants from Indian ethnicity cases
The BIC and the ClinVar databases contain DNA sequence
variations reported by genetics clinics from across the
world. The majority of the DNA variants in these repositor-
ies are unpublished. The most frequent reported entry in
BIC for the BRCA1 gene was 185delAG, which was also the
most prevalent in our analysis (Table 8). Eight out of the 20
Table 5. Novel likely pathogenic BRCA1 variants.
BRCA1 Exon/
intron
HGVS annotation
cDNA
Protein Variant type Number of studies
contributing to the
total number of
cases
Total cases
(does not
include controls)
Carrier
2 c.3672G>T p.Glu1185Stop N 1 65 1
7 c.512dupT p.Gln172ThrfsTer10 Indel 1 141 1
10 c.779dupA p.Tyr261ValfsTer1 Indel 1 141 1
10 c.1155G>A p.Trp385Ter NS 1 141 1
10 c.1416delC p.Asn473ThrfsTer2 Indel 1 141 1
12 c.4349C4A p.Ser1450Ter F 1 141 1
22 c. 5440dupG p. Ala1814GlyfsTer16 SS 1 141 1
16 4956insG TGA at codon F 1 124 1
11 4213delT Leu.1365->Stop N 1 61 1
18 5267T->G p.Tyr1716Ter N 1 61 1
11 1027delA delA-ter313 (codon303) F 1 14 1
16 4956insG/c.4183C>T p.Gln1395Ter F 1 124 1
20 5339G>T>G p.Glu754Ter M 1 40 1
11 3867G>T p.Glu250Ter N 1 40 1
5 (nucleotide) 295delCA Translation stop at
codon 64
F 1 61 1
11 1052delT Stop313 F 1 151 2
8 632insT Stop181 F 1 151 4
N = Nonsense, F = frameshift, SS = splice site, IVS = Intervening sequence ie. the intron, Indel = insertion and deletion.
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top entries in BIC were also detected in our literature sur-
vey, although not all of these variants were shown to be
pathogenic (Table 8). None of the pathogenic BRCA2 var-
iants identiﬁed from our literature search were present in
the top 20 BIC entries for BRCA2 (Table 9).
A search in BIC using the keyword ‘Indian’ in the eth-
nicity ﬁeld revealed 23 BRCA1 variants and 11 BRCA2 var-
iants. All these variants were detected in patients of
Indian descent from Singapore or Malaysia. Seven of the
BRCA1 variants were present in our dataset collated
from the literature (Tables 10 and 11). However, of the
seven variants that overlapped, only two (180delA and
185delAG) were classed as pathogenic in BIC and ClinVar
(Tables 10 and 11). Of the 11 BRCA2 variants present in
BIC with Indian ethnicity, three were also present in our
literature dataset and of the three only one was classed
as pathogenic, Q2957X. Another interesting observation
was that the BRCA2 variant E1593D present in both our
dataset and in the subset of 11 BIC variants, was also
reported in two additional Pakistani patients in BIC.
The same search performed in ClinVar with ‘Indian’
detected 40 variants for BRCA1 and 30 for BRCA2, which
included all variants also present in BIC.
Individual searches in additional databases such as
TCGA, ICGC, dbSNP, GWAS catalogue, COSMIC, and
HGMD did not yield any results. Although these data-
bases contain ethnicity data, they use a very broad deﬁn-
ition of ‘Asians’, yet the ethnicity data in the 1000genome
database are region-speciﬁc and therefore this makes
comparisons difﬁcult. Furthermore, there were no data in
ICGC on breast and ovarian cancers from India.
Details of family history, penetrance, and survival
in included studies
Studies in the literature used very heterogeneous cri-
teria to deﬁne a family history of disease. Mutation
prevalence in women with a family history of breast
and/or ovarian cancer was presented in 11 of the 13
studies, but only seven of these provided clear criteria
for family history (≥1 ﬁrst degree relative affected with
breast or ovarian cancer at any age). Women with spor-
adic breast or ovarian cancer were reported in seven
publications. None of the 13 studies provided pene-
trance data. One small study with 91 patients presented
survival information and found no signiﬁcant associ-
ation with pathogenic BRCA1 or BRCA2 mutations.25
Histopathology
Two studies27,28 provided some data on breast cancer
histopathology, with none describing complete histo-
logical details such as grade of cancer, hormone recep-
tor, and HER2 status. Eachkoti et al. reported the
majority of cases (22/25) to be inﬁltrating ductal carcin-
oma (IDC) with two inﬂammatory carcinomas (an
aggressive type of breast cancer) and one Paget’s dis-
ease. Similarly Thirthagiri et al. identiﬁed IDC as the
commonest histological type for both BRCA1 and BRCA2T
ab
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carriers. Where grade was available, tumours were of
grade 2 and 3, with no grade 1 tumours identiﬁed.
BRCA1 tumours were largely triple negative and less
commonly HER2 positive, whereas BRCA2 tumours were
more likely to be hormone receptor positive. The data,
however, were not available for the three markers in
eight cases and for at least one of the three markers in
an additional seven cases out of the total 28 tumours
included. No studies were identiﬁed including informa-
tion on the histology of ovarian tumours.
Table 7. Novel likely pathogenic BRCA2 variants.
BRCA2 EXON/
Intron
HGVS annotation
cDNA
Protein Variant
type
Number of studies
contributing to the
total number of
cases
Total cases
(does not
include
controls)
Carrier
11 c.5076delAA stop1617 F 151 1
25 c.9608G>A p.Trp3127Ter N 151 1
11 63761insAA Stop 2051 F 1 204 1
19 c.85761nsC Stop 2797 F 1 204 1
27 9999delA Stop3275 F 1 204 1
11 c.3187C>T p.Gln1063Ter NS 141 1
11 c.3186_3189delTCAG p.Ser1064LeufsTer12 Indel 141 1
11 c.4642delAA Stop1480 F 102 1
11 c.4926insGACCC Stop1575 F 102 1
11 c.5227dupT Stop1676 1 65 1
11 c.5242dupT Stop1676 1 65 1
11 c.6180dupA Stop2002 1 65 1
22 nt 9097 Gln2957 F, N and SS 1 22 1
11 4866InsT Asp1547Ter FS 1 61 1
11 c.4642delAA Stop1480 F 1 102 1
11 c.4926insGACCC Stop1575 F 1 102 1
N = Nonsense, F = frameshift, SS = splice site, IVS = Intervening sequence ie. the intron, Indel = insertion and deletion.
Table 8. Top 20 BIC entries for BRCA1.
BIC designation Number of entries in BIC Number of studies Total cases
(excluding controls)
Number of carriers Pathogenicity
1 185delAG 2038 10 840 39 Pathogenic
2 5382insC 1093 1 92 7 Pathogenic
3 4427T>C 251
4 S1613G 248 2 226 2 Benign
5 C61G 239
6 2430T>C 229
7 2201C>T 227
8 IVS18+66G>A 222 1 124 3 Benign
9 IVS16-68A>G 216
10 IVS16-92A>G 216
11 IVS8-58delT 214
12 P871L 211 1 22 7 Benign
13 IVS7-34C>T 207 1 124 5 Benign
14 E1038G 182 1 22 12 Benign
15 K1183R 164 1 204 16 Benign
16 R1347G 161
17 Q356R 155
18 4184del4 144
19 M1008I 139
20 R1443X 136
Bold face indicates variants also identiﬁed in our literature search.
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Discussion
We have reported the ﬁndings of a methodical review of
reported germline variants in BRCA1, BRCA2, and other
high-penetrance breast and ovarian cancer susceptibil-
ity genes within women of Indian descent. Our searches
highlight both the diversity of the Indian population as
well as the paucity of data on germline variants in these
genes in the Indian population. There are very limited
Indian-speciﬁc data and, even where these are avail-
able, there is great variability in inclusion criteria, deﬁn-
ition of high-risk groups (such as those with a family
history), mutation detection methods, geographical ori-
gin, and ethnicity, thus making any India-wide assess-
ment unreliable. The small cohort size mean that the
spectrum of mutations identiﬁed in BRCA genes is
unlikely to be representative of the Indian population
and is indeterminate for other high-risk susceptibility
genes in this population. Our searches have identiﬁed
18 BRCA1 and 16 BRCA2 variants in the Indian popula-
tion that had not been previously reported elsewhere,
nor currently present in BIC or ClinVar. There were no
studies of sporadic or unselected cases and also very
limited data on penetrance or survival that could be
used for calculating cancer risks and hence implement-
ing counselling and screening in Indian populations.
The spectra of BRCA1 and BRCA2 mutations have
been characterized in a number of different populations
worldwide, with signiﬁcant variation among populations
in the contributions of these genes to hereditary breast
and ovarian cancer.29 Founder mutations account for
differing proportions of cancer in different populations;
for example in the Ashkenazi Jewish population [12],
three founder mutations have a combined population
frequency of 2% and represent 60% of breast cancer fam-
ilies with a BRCA1 or BRCA2 gene mutation. Similarly,
BRCA1 and BRCA2 founder mutations account for 78% of
families with hereditary breast cancer in Chile.30
Our search reveals a much lower frequency (2.3%; 39/
1700) of the putative Ashkenazi founder mutation
185delAG in Indian patients with breast and/or ovarian
cancer. The carriers of this mutation were usually from
the south of India. Other studies have explored how
this variant arose in the Indian population. Kadalmani
et al. examined the haplotypes of carriers of this variant
and their families, and concluded that it arose inde-
pendently from the Ashkenazi variant. Another study
by Laitman et al. came to a similar conclusion based on
haplotype analyses of carriers from ethnically diverse
backgrounds, which included Indians from Cochin,
south India.31,32 Other founder BRCA1 and BRCA2 muta-
tions were not detected in any of the Indian patients
with breast and ovarian cancers, and no India-speciﬁc
founder mutations were detected.
Our literature search shows that variation in the
prevalence of high-penetrance alleles in genes such as
BRCA1 and BRCA2 may contribute to the reported differ-
ences in breast and ovarian cancer incidence across
India, in Indians in other countries, and between India
and the west. The earlier average age of breast cancer
among Indian women is especially intriguing in this
respect. Data are, however, very limited and have not
Table 9. Top 20 BIC entries for BRCA2.
BIC designation Count Number of
studies
Total cases
(excluding controls)
Number
of carriers
Pathogenicity
1 6174delT 1093
2 H372N 396 1 22 13 Benign
3 10590A>C 346
4 F599S 345
5 IVS16-14T>C 332
6 IVS21-66T>C 319
7 K3326X 301
8 I2490T 240
9 3624A>G 234
10 IVS11+80delTTAA 221
11 203G>A 206
12 D1420Y 200 1 102 3 Benign
13 E2856A 186
14 7470A>G 183
15 4035T>C 161
16 Y42C 144
17 S384F 143
18 IVS8+56C>T 143
19 P655R 142
20 I505T 128
Total database entries 14 914
Bold face indicates variants also identiﬁed in our literature search.
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Table 10. BIC searching with keyword ‘Indian’ for BRCA1.
Exon HGVS cDNA HGVS Protein Mutation BIC Designation BIC Class Database dbSNP ClinVar Classiﬁcation
BRCA1 2 c.61_61delA p.Ile21Serfs F 180delA 3 BIC - Pathogenic
2 c.66_67delAG p.Leu22_Glu23LeuValfs F 185delAG 5 BIC rs80357713 Pathogenic
5 c.150_150delA p.Lys50Asnfs F 269delA 5 BIC - Pathogenic
11A c.685_685delT p.Ser229Leufs F 804delT 5 BIC rs80357824 Pathogenic
11C c.2766_2766delA p.Thr922 = fs F 2885delA 5 BIC rs80357812 Pathogenic
11A c.1054G>T p.Glu352Ter N E352X Class 5 BIC rs80357472 Pathogenic
20 c.5251C>T p.Arg1751Ter N R1751X Class 5 BIC rs80357123 Pathogenic
24 c.5559C>A p.Tyr1853Ter N Y1853X Pending BIC rs80357336 Pathogenic
11A c.823G>A p.Gly275Ser M G275S Pending BIC rs8176153 Conﬂicting interpretations of pathogenicity
11C c.2612C>T p.Pro871Leu M P871L Class 1 BIC rs799917 Benign
11C c.3113A>G p.Glu1038Gly M E1038G Pending BIC rs16941 Benign
11D c.3548A>G p.Lys1183Arg M K1183R Pending BIC rs16942 Benign
15 c.4643C>T p.Thr1548Met M T1548M Pending BIC Uncertain signiﬁcance
16 c.4837A>G p.Ser1613Gly M S1613G Pending BIC rs1799966 Benign
5 c.135-1G>C IVS IVS4-1G>C Pending BIC Pathogenic
6 c.213-161A>G IVS IVS5-161A>G Class 1 BIC Benign
9 c.548-57_548-57delT IVS IVS8-57delT Pending BIC Benign
13 c.4097-141A>C IVS IVS12-141A>C Pending BIC Benign
13 c.4186-10G>A IVS IVS12-10G>A Pending BIC rs80358172 Conﬂicting interpretations of pathogenicity
15 c.4485-90T>C IVS IVS14-90T>C Pending BIC Uncertain signiﬁcance
15 c.4485-64C>G IVS IVS14-64C>G Pending BIC Uncertain signiﬁcance
11B c.2311T>C p.Leu771 = Syn 2430T>C Class 1 BIC rs16940 Benign
13 c.4308T>C p.Ser1436 = Syn 4427T>C Class 1 BIC rs1060915 Benign
Bold face indicates variants also identiﬁed in our literature search
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been collected systematically in terms of inclusion cri-
teria, details such as family history, and critical clinical
co-variates such as histopathology. Furthermore, very
limited work has been published to address environ-
mental risk factors speciﬁc to the Indian population and
distinct from Western populations, such as consanguin-
eous marriage, betel quid consumption, and pregnan-
cies. Current guidelines on cancer screening and
prevention in gene carriers are based on evidence pre-
dominantly derived from white populations of northern
European origins. Work is needed to modify existing
risk-prediction models such as Manchester or BOADICEA
for use in women of different ethnicities. Indeed, previ-
ous work has found that overall sensitivity, speciﬁcity,
and positive-predictive values were lower in the Asian
population than in Caucasian populations.26 In conclu-
sion, there is an urgent unmet need for large-scale stud-
ies in geographically distinct regions, with high-quality
data and longitudinal studies of relatives to help eluci-
date the role of breast and ovarian cancer susceptibility
genes in the Indian population. Understanding these differ-
ences through research to derive India-speciﬁc paradigms
for diagnosis, screening, prevention, and treatment is crit-
ical and essential to improving women’s health in India.1
Clinics in countries with the Indian diaspora and estab-
lished clinical genetics services may be able to contribute to
penetrance and survival data and further tease out the dif-
ferences in environmental risk factors between Indian dias-
pora and Indian patients.
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Supplementary data are available at Precision Clinical
Medicine online.
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